Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an...
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Target Price
The average target price of RCUS is 33 and suggests 36% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell